CRISPR Therapeutics Q2 revenue misses estimates, net loss widens

Reuters

Aug 05

CRISPR <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> revenue misses estimates, net loss widens

Overview

CRISPR Q2 revenue missed analyst expectations, reflecting financial challenges, per LSEG data
Net loss for Q2 increased to $208.5 mln compared to last year
Co achieved milestone with 75 authorized treatment centers for CASGEVY therapy

Outlook

CRISPR Therapeutics anticipates presenting CTX310 Phase 1 data in H2 2025
Company plans CTX112 updates in oncology and autoimmune diseases in H2 2025
CRISPR Therapeutics expects CTX320 update in H1 2026

Result Drivers

CASGEVY EXPANSION - Activation of 75 authorized treatment centers globally for CASGEVY therapy, marking a milestone in commercial rollout

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Miss	$892,000	$6.25 mln (18 Analysts)
Q2 EPS		-$2.4
Q2 Basic EPS		-$2.4
Q2 Operating Expenses		$230.22 mln
Q2 Pretax Profit		-$207.26 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CRISPR Therapeutics AG is $79.50, about 29.4% above its August 1 closing price of $56.09

Press Release: ID:nGNX85Nwmd

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557331928"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557331928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557331928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557331928","market":"us","top_or_hot":-1,"title":"CRISPR Therapeutics Q2 revenue misses estimates, net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue misses estimates, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>CRISPR Q2 revenue missed analyst expectations, reflecting financial challenges, per LSEG data</p></li><li><p>Net loss for Q2 increased to $208.5 mln compared to last year</p></li><li><p>Co achieved milestone with 75 authorized treatment centers for CASGEVY therapy</p></li></ul><p><span>Outlook</span></p><ul><li><p>CRISPR Therapeutics anticipates presenting CTX310 Phase 1 data in H2 2025</p></li><li><p>Company plans CTX112 updates in oncology and autoimmune diseases in H2 2025</p></li><li><p>CRISPR Therapeutics expects CTX320 update in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASGEVY EXPANSION - Activation of 75 authorized treatment centers globally for CASGEVY therapy, marking a milestone in commercial rollout</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>$892,000</p></td><td><p>$6.25 mln (18 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$2.4</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$2.4</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$230.22 mln</p></td><td></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td></td><td><p>-$207.26 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 11 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for <a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a> is $79.50, about 29.4% above its August 1 closing price of $56.09</p></li></ul><p>Press Release: <span>ID:nGNX85Nwmd</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRISPR Therapeutics Q2 revenue misses estimates, net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRISPR Therapeutics Q2 revenue misses estimates, net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 04:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue misses estimates, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>CRISPR Q2 revenue missed analyst expectations, reflecting financial challenges, per LSEG data</p></li><li><p>Net loss for Q2 increased to $208.5 mln compared to last year</p></li><li><p>Co achieved milestone with 75 authorized treatment centers for CASGEVY therapy</p></li></ul><p><span>Outlook</span></p><ul><li><p>CRISPR Therapeutics anticipates presenting CTX310 Phase 1 data in H2 2025</p></li><li><p>Company plans CTX112 updates in oncology and autoimmune diseases in H2 2025</p></li><li><p>CRISPR Therapeutics expects CTX320 update in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASGEVY EXPANSION - Activation of 75 authorized treatment centers globally for CASGEVY therapy, marking a milestone in commercial rollout</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>$892,000</p></td><td><p>$6.25 mln (18 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$2.4</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$2.4</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$230.22 mln</p></td><td></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td></td><td><p>-$207.26 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 11 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for <a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a> is $79.50, about 29.4% above its August 1 closing price of $56.09</p></li></ul><p>Press Release: <span>ID:nGNX85Nwmd</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRSP","symbol_name":"CRISPR Therapeutics AG","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nPLXEB53BD:1","article_id":"2557331928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557331928","pubTimestamp":1754339161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CRISPR TherapeuticsQ2 revenue misses estimates, net loss widensOverviewCRISPR Q2 revenue missed analyst expectations, reflecting financial challenges, per LSEG dataNet loss for Q2 increased to $208.5 ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"translate_title":"CRISPR Therapeutics第二季度收入未达预期，净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":0.9},"content_text":"CRISPR Therapeutics Q2 revenue misses estimates, net loss widensOverviewCRISPR Q2 revenue missed analyst expectations, reflecting financial challenges, per LSEG dataNet loss for Q2 increased to $208.5 mln compared to last yearCo achieved milestone with 75 authorized treatment centers for CASGEVY therapyOutlookCRISPR Therapeutics anticipates presenting CTX310 Phase 1 data in H2 2025Company plans CTX112 updates in oncology and autoimmune diseases in H2 2025CRISPR Therapeutics expects CTX320 update in H1 2026Result DriversCASGEVY EXPANSION - Activation of 75 authorized treatment centers globally for CASGEVY therapy, marking a milestone in commercial rolloutKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueMiss$892,000$6.25 mln (18 Analysts)Q2 EPS-$2.4Q2 Basic EPS-$2.4Q2 Operating Expenses$230.22 mlnQ2 Pretax Profit-$207.26 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 11 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for CRISPR Therapeutics AG is $79.50, about 29.4% above its August 1 closing price of $56.09Press Release: ID:nGNX85Nwmd(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}